T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.14% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alphabet (Google) Class C
GOOG
$3.99T
| $10.9B | 2.35% |
375,719,153
+1,454,114
| +0.4% | +$39.5M |
|
2
Amazon
AMZN
$2.49T
| $7.6B | 1.64% |
468,121,700
+36,489,660
| +8% | +$577M |
|
3
Booking.com
BKNG
$145B
| $5.71B | 1.23% |
118,738,875
+11,242,125
| +10% | +$540M |
|
4
Gilead Sciences
GILD
$162B
| $5.55B | 1.2% |
66,996,617
-6,908,810
| -9% | -$538M |
|
5
Danaher
DHR
$138B
| $5.33B | 1.15% |
100,815,681
-65,333
| -0.1% | -$3.36M |
|
6
Visa
V
$689B
| $4.96B | 1.07% |
94,145,812
+11,833,288
| +14% | +$619M |
|
7
Apple
AAPL
$4.95T
| $4.82B | 1.04% |
207,426,920
-27,736,232
| -12% | -$590M |
|
8
Boeing
BA
$167B
| $4.68B | 1.01% |
36,781,208
+2,816,041
| +8% | +$368M |
|
9
McKesson
MCK
$99.5B
| $4.18B | 0.9% |
22,427,492
+1,394,637
| +7% | +$248M |
|
10
JPMorgan Chase
JPM
$947B
| $4.1B | 0.89% |
71,088,855
+10,067,247
| +16% | +$566M |
|
|
PXD
11
DELISTED
Pioneer Natural Resource Co.
PXD
| $3.96B | 0.86% |
17,230,352
+101,553
| +0.6% | +$21M |
|
12
RTX Corp
RTX
$294B
| $3.86B | 0.83% |
53,141,404
+2,713,463
| +5% | +$200M |
|
13
Biogen
BIIB
$29.5B
| $3.85B | 0.83% |
12,194,641
+16,492
| +0.1% | +$4.96M |
|
14
Baidu
BIDU
$35.8B
| $3.55B | 0.77% |
18,995,931
+2,572,338
| +16% | +$421M |
|
15
GE Aerospace
GE
$375B
| $3.36B | 0.73% |
26,691,916
+1,613,086
| +6% | +$205M |
|
|
PCP
16
DELISTED
PRECISION CASTPARTS CORP
PCP
| $3.32B | 0.72% |
13,144,629
-745,731
| -5% | -$191M |
|
17
PepsiCo
PEP
$191B
| $3.25B | 0.7% |
36,366,145
-3,268,798
| -8% | -$282M |
|
18
American Tower
AMT
$77.7B
| $3.13B | 0.68% |
34,823,898
-812,458
| -2% | -$70.3M |
|
|
19
American Airlines Group
AAL
$9.9B
| $3.1B | 0.67% |
72,179,038
+21,866,091
| +43% | +$853M |
|
20
UnitedHealth
UNH
$379B
| $2.97B | 0.64% |
36,321,951
-5,321,672
| -13% | -$419M |
|
21
Meta Platforms (Facebook)
META
$1.51T
| $2.95B | 0.64% |
43,865,171
+1,457,215
| +3% | +$89.6M |
|
22
ExxonMobil
XOM
$642B
| $2.9B | 0.63% |
28,760,079
-616,195
| -2% | -$62.2M |
|
23
Wells Fargo
WFC
$264B
| $2.86B | 0.62% |
54,434,732
+4,054,864
| +8% | +$204M |
|
24
Lowe's Companies
LOW
$119B
| $2.77B | 0.6% |
57,636,197
+3,486,801
| +6% | +$163M |
|
25
Mastercard
MA
$487B
| $2.73B | 0.59% |
37,151,271
-2,459,179
| -6% | -$183M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.